InsidersTradesSigma
Track the Aziyo Biologics, INC. share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Aziyo Biologics, INC. has published 22 public disclosures. The latest transaction was reported on 23 June 2023 (Levée d'options). Among the most active insiders: Ferguson Matthew. The full history is openly available.
22
Insider Decl.
n/a
Thresholds
€5m
9 ops.
Buy Volume
n/a
n/a
Sell Volume
46Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 23 June 2023
Declarations22 total
22,474 sharesClass A Common StockSEC:0001415889-23-010225:0
44,947 shares0Class A Common StockSEC:0001415889-23-007019:0
100,000 shares@ US$1.49199.2% of flowClass A Common StockSEC:0001104659-23-037129:0
Canonical exit: 21 Jun 2023 (T+90)
1,287 shares0Class A Common StockSEC:0001415889-23-004624:0
937 shares0Class A Common StockSEC:0001415889-23-004626:0
200 shares@ US$5.96040.8% of flowClass A Common StockSEC:0001104659-23-019991:0
Canonical exit: 9 Aug 2022 (T+90)
3,098 shares@ US$3.90100.0% of flowClass A Common StockSEC:0001415889-22-012640:0
Canonical exit: 15 Mar 2023 (T+90)
2,000 shares@ US$3.65100.0% of flowClass A Common StockSEC:0001415889-22-012417:0
Canonical exit: 9 Mar 2023 (T+90)
735,000 shares@ US$4.7555.4% of flowClass A Common StockSEC:0001104659-22-125197:0
Canonical exit: 5 Mar 2023 (T+90)
6,000 shares@ US$4.0349.0% of flowClass A Common StockSEC:0001415889-22-012089:0
Canonical exit: 2 Mar 2023 (T+90)
14,758 sharesClass A Common StockSEC:0001415889-22-009536:0
15,390 sharesClass A Common StockSEC:0001415889-22-009538:0
13,874 sharesClass A Common StockSEC:0001415889-22-009542:0
4,625 sharesClass A Common StockSEC:0001415889-22-009540:0
782 shares0Class A Common StockSEC:0001415889-22-002862:0
938 shares0Class A Common StockSEC:0001415889-22-002866:0
4,072 shares0Class A Common StockSEC:0001415889-22-002864:0
1,288 shares0Class A Common StockSEC:0001415889-22-002860:0
938 shares0Class A Common StockSEC:0001415889-22-002868:0
4,580 shares@ US$6.1050.0% of flowClass A Common StockSEC:0001415889-21-005960:0
Canonical exit: 14 Mar 2022 (T+90)
353,773 shares@ US$4.2450.0% of flowClass A Common StockSEC:0001104659-21-148591:0
Canonical exit: 8 Mar 2022 (T+90)
1,300 shares@ US$11.1434.2% of flowClass A Common StockSEC:0001104659-21-065258:0
Canonical exit: 8 Aug 2021 (T+90)
22 of 22 declarations
关于 Aziyo Biologics, INC.
Aziyo Biologics, Inc. 是一家在美国上市的医疗保健/医疗技术公司，历史上曾在纳斯达克上市，股票代码为 AZYO。公司总部位于马里兰州银泉，其建立围绕着一个独特的理念：利用生物组织来改善植入式医疗设备与患者之间的兼容性。从股票研究的角度来看，Aziyo 长期以来一直处于再生医学、生物材料和外科护理的交汇点，其商业模式依赖于医疗服务提供商、外科医生和选定的战略合作伙伴。([sec.gov](https://www.sec.gov/Archives/edgar/data/1708527/000155837022003073/azyo-20211231x10k.htm?utm_source=openai)) 其业务围绕着一系列源自人类和猪组织生物产品。这些产品服务于多个终端市场，包括植入式电子设备和心血管手术、骨科和脊柱修复以及软组织重建。Aziyo 的核心业务包括旨在支持愈合、减少并发症和改善设备-组织整合的生物包膜和基于组织的重建产品。此外，公司还拥有非核心和合同制造业务，这扩大了其在主要品牌产品之外的商业足迹。([sec.gov](https://www.sec.gov/Archives/edgar/data/1708527/000155837022003073/azyo-20211231x10k.htm?utm_source=openai)) 竞争定位以专业化为核心。Aziyo 没有作为广泛的医疗设备平台进行竞争，而是专注于利基再生解决方案，其中临床证据、监管状况和分销伙伴关系至关重要。这种专注使公司能够进入高价值、技术要求高的市场，但也意味着执行风险较高：产品采用取决于外科医生的接受度、报销动态、监管里程碑以及通过合作伙伴扩大规模的能力。公司强调了与 Medtronic、Sientra 和 LeMaitre Vascular 的合作，突显了将专有开发与成熟商业渠道相结合的上市战略。([investors.aziyo.com](https://investors.aziyo.com/news-releases/news-release-details/aziyo-biologicsr-announces-exclusive-agreement-medtronicr?utm_source=openai)) 近期里程碑集中在 CanGaroo RM 上，这是一种用于植入式电子设备的下一代抗菌生物材料包膜。在 2022 年和 2023 年，Aziyo 描述了某些业务部门的监管进展、产品开发更新和商业吸引力。与此同时，公司还在 2023 年 7 月披露了对一些可存活骨基质产品的自愿召回，这提醒人们产品质量和制造执行是该领域的关键关注点。2023 年 9 月，Aziyo 宣布更名为 Elutia，作为向药物洗脱生物基质战略转变的一部分，这对于监控 SEC Form 4 文件和公司发展的投资者来说是一个重要的背景。总的来说，AZYO 这个名称代表了一个小盘股、高度专业化的美国医疗保健故事，具有巨大的上行潜力，但也存在明显的监管、运营和商业风险。([investors.aziyo.com](https://investors.aziyo.com/news-releases/news-release-details/aziyo-announces-fda-510k-submission-cangaroor-rm-its-next?utm_source=openai))
